From a zero-landfill plant to the historic goal of a zero-landfill National Park system, experience over a decade of our enviromental ingenuity. Explore.
Interestingly, Abou-Elella et al (11) could not confirm that the clinical course of PMLBCL was distinct from diffuse large B-cell lymphoma (DLBCL). Treatment of the lymph node cancer called diffuse large B-cell lymphoma is all-or-nothing. Genes make potential target in lymph cancer. Despite this, indolent disease is typically incurable, with the most aggressive lymphoma subtype - diffuse large B-cell lymphoma having 5-year survival rates of -50%.
We aimed to investigate the clinical significance of fascin expression in CD20 positive diffuse large B-cell lymphomas (DLBCL) in patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone plus rituximab (R-CHOP). Thirtyfour of the 55 patients included in the study showed fascin expression, 16 of them being diffuse and strong.